MBP8298
Other names:
In development for: Relapsing/remitting MS and secondary progressive MS
Status: Phase III
Last updated: April 2008
How does it work?
Myelin basic protein (MBP) is believed to be important in the process of myelination of nerves in the brain and spinal cord. MBP9298 is a copy of part of MBP and is thought to act by causing or restoring tolerance to immune attack at this section of MBP.
How is it given?
Intravenous infusion every six months.
Clinical studies
In a phase II clinical trial, 32 people with progressive MS received an infusion of MBP8298 every six months for 24 months. A statistically significant delay in clinical progression was found in people with a particular genetic makeup (65-75% of all people with MS). In this subgroup, MBP8298 treatment resulted in a delay of progression (78 months for MBP8298 vs 18 months for placebo).
Three clinical trials are currently underway: two phase III clinical trials of MBP8298 in secondary progressive (one in Canada and Europe and the other in the USA) and one phase II clinical trial in relapsing/remitting MS (in Europe).
References
Warren KG, et al.
Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.
European Journal of Neurology 2006; 13(8): 887-895.
Read abstract
